Educational content only — this is not medical advice. Nothing here is a recommendation to buy, obtain, or use Ipamorelin. Talk to a licensed clinician before making health decisions.
What it is
Ipamorelin is a pentapeptide designed to mimic ghrelin and stimulate growth hormone release from the pituitary via the GHS-R1a receptor. It is promoted for its selectivity — it is said to raise GH without significantly increasing cortisol, prolactin, or aldosterone in animal models. It has a short half-life and is usually injected multiple times daily.
What the evidence shows
The published evidence is almost entirely preclinical. Rodent and dog studies show dose-dependent GH release with minimal effects on other pituitary hormones. A small number of older human pharmacodynamic studies confirmed GH elevation, but no robust RCT has evaluated body composition, performance, or long-term safety in people. Claims of fat loss, muscle gain, and recovery are unproven in humans.
Risks & unknowns
Human safety data are limited. By raising GH and IGF-1, ipamorelin could cause water retention, joint pain, insulin resistance, and increased appetite. Long-term effects on pituitary function, metabolism, and cancer risk are unknown. Product quality from gray-market sources is unreliable.
Legal / regulatory status
Ipamorelin is not FDA-approved and is prohibited in sport by WADA under S2. It is not legal to market for human use.